BONNIE J. ADDARIO LUNG CANCER FOUNDATION COLLABORATING WITH PATIENT DRIVEN GROUP TO IMPROVE CARE FOR PEOPLE WITH EGFR-POSITIVE LUNG CANCER
The state of today’s medicine is still improving with its numerous research to combat complicated diseases that affect the industry and the humanity.
In a news release, the Bonnie J. Addario Lung Cancer Foundation (ALCF) and the EGFR Resisters, a patient advocate group of people living with epidermal growth factor receptor (EGFR) positive lung cancer and their loved ones are joining forces in raising funds and increasing awareness of projects benefiting the EGFR community.
“ALCF was founded to bring lung cancer patients into the conversation,” said Bonnie J. Addario, 14-year lung cancer survivor and ALCF founder. “We exist to support patient collaboration, and our partnership with the EGFR Resisters is a perfect example of that principle in action.”
Based on research, EGFR gene mutations are commonly found in patients with non-small cell lung cancer, making up to 15 % of patients in the United States and 35 % of patients in Asia. While lung cancers with the EGFR mutation often respond well to specifically targeted therapies, patients commonly acquire resistance as additional genetic mutations develop that block the therapy’s benefits. These conditions pushed researchers to look for new treatments that overcome therapy resistance.
“We’re excited about the possibilities this collaboration offers,” said Ivy Elkins, one of the EGFR Resisters founders and an advocate for lung cancer patients. “My hope is that patients around the globe will join forces with the EGFR Resisters to create a strong collective voice in support of research. Working with ALCF strengthens our voice and extends our reach into important corridors of medical research and funding.”
The combining efforts of ALCF and its research support, Addario Lung Cancer Medical Institute (ALCMI), with the patient advocacy of several hundred people around the world who have come together to form the EGFR Resisters will enable greater outreach to obtain research funding, raises awareness about the patients who have donated information and tissue samples and provides researchers a channel to recruit volunteers in participating clinical trials for new therapies.
“Patients who are EGFR positive are a unique subset of lung cancer patients,” said Pasi A. Jänne, M.D., PhD., EGFR Resisters medical advisor, director of the Lower Center for Thoracic Oncology at Dana-Farber Cancer Institute and a professor of medicine at Harvard Medical School. “Many patients with EGFR enjoy a dramatic response to targeted therapy, followed by a profound letdown when the therapy stops working. Through this partnership, we can help to replace that disappointment with hope.”
Erduite Nursing Institute™ calls nurse researchers to support this latest research concerning EGFR-positive lung cancer patients, raising awareness and increasing funds for numerous projects in order to create advance treatments in the future.
Note: The foregoing article is copyrighted and may not be reproduced in part or entirety without advance written permission. For permissions or editorial corrections, contact: Ms. Kelsey Hanna, khanna@EruditeNursing.education